Izalontamab Biosimilar Bispecific Antibody (EGFR × HER3) for Research

Cat No.: GMP-Bios-INN-1245

Anti-EGFR/ERBB1/HER1 therapeutic antibody (Pre-made Izalontamab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Izalontamab (development code SI-B001) is a bispecific antibody targeting EGFR and HER3 (ERBB3). It is developed by Systimmune for colorectal cancer, non-small cell lung cancer, and head and neck cancers. It is in Phase III clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1245-1mg 1mg
GMP-Bios-INN-1245-10mg 10mg
GMP-Bios-INN-1245-100mg 100mg
GMP-Bios-INN-1245-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Izalontamab biosimilar, Bispecific Mixed mAb and scFv, Anti-EGFR/ERBB1/HER1;ERBB3/HER3 Antibody: Anti-EGFR/Epidermal growth factor receptor/Proto-oncogene c-ErbB-1/Receptor tyrosine-protein kinase erbB-1 therapeutic antibody
INN Name Izalontamab
Target EGFR/ERBB1/HER1;ERBB3/HER3
Format Bispecific Mixed mAb and scFv
Derivation Chimeric
Species Reactivity Human
CH1+2+3 Isotype G1;na
VD LC Kappa;Lambda
Highest_Clin_Trial (Jan '20) Phase-III
Est. Status Active
100% SI Structure 5etu:DC:BA/5ff6:DC:BA/5f88:DC:BA/5itf:DC:BA/5ivz:DC:BA/5ir1:DC:BA/5esq:DC:BA/5euk:DC:BA/5hpm:DC:BA/5id1:DC:BA/5icx:DC:BA/5hyq:DC:BA/5icz:DC:BA/5th2:DC:BA/5iop:DC:BA/5i2i:DC:BA/5t1l:DC:BA/5i76:DC:BA/5iv2:DC:BA/5t1k:DC:BA;None
99% SI Structure 6azk:DC:BA/6azl:BA:DC/6au5:DC:BA/6ayn:BA:DC/6axp:BA:DC/5id0:DC:BA/5t1m:DC:BA/5icy:DC:BA/1yy8:DC:BA/1yy9:DC/4gw5:DC:BA/4kro:DC/4gw1:DC:BA/4krp:DC;None
95-98% SI Structure 5gz0:BA:DC/6arp:BA:DC/6aru:CB;None
Year Proposed 2022
Year Recommended 2022
Companies Systimmune
Conditions Approved na
Conditions Active Colorectal cancers;Non-small cell lung cancers;Head and neck cancers;Esophageal squamous cell carcinoma
Conditions Discontinued na
Production na
Development Tech na